Skip to content
Peptide research

Epithalon

Also known as Epitalon · Epithalone · AEDG Peptide
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic four-amino-acid peptide marketed for anti-aging and sleep, said to activate telomerase (the enzyme that rebuilds chromosome caps) and raise melatonin. Most evidence is from animals and cells, and nearly all human data is from one unreplicated Russian group. There are no large human safety trials, and switching on telomerase raises a theoretical cancer-growth risk. Not an approved US drug, and most supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Epithalon is a short synthetic peptide made of just four amino acids, originally developed from an extract of the pineal gland — the small brain structure that regulates your sleep-wake rhythm. It is studied primarily for its ability to activate telomerase, the enzyme that maintains telomeres — the protective caps on the ends of your chromosomes that shorten each time cells divide. This shortening is considered one of the fundamental mechanisms of biological aging.

How it works in the body

Activates telomerase, the enzyme that rebuilds telomeres (protective caps on chromosome ends that shorten with each cell division). By lengthening telomeres, it extends the number of times a cell can divide before becoming senescent. It also stimulates melatonin production from the pineal gland.

Research overview

Epithalon induced telomerase activity and telomere elongation in cultured human fetal fibroblasts. A small human study reported a 1.7-fold rise in urinary melatonin metabolite, without measuring sleep improvement. Antioxidant and immune effects are mainly preclinical. Research on epithalamin extract should be distinguished from studies of this synthetic peptide. Independent cell-culture research appeared in 2025.

Who researches Epithalon?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching experimental oncology peptides

    Studied for effects on cancer cell targeting or tumor biology in preclinical research.

Important considerations for

  • Those with Active cancer

    Moderate

    Telomerase activation could theoretically promote cancer cell immortality, though evidence is mixed.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data.

Safety & interactions

Do not use if

  • Active cancer

    Moderate

    Telomerase activation could theoretically promote cancer cell immortality, though evidence is mixed.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • No large-scale safety studies in humans

    High

    2025 review PMC11943447 (toxicology gap noted in Future Perspectives); FDA (no approval)

  • Theoretical risk: telomerase activation could accelerate pre-existing cancer

    Theoretical

    Mechanism-based; animal antitumor data in 2025 review PMC11943447

  • Almost all human data from a single Russian research group (no independent replication)

    High

    2025 review PMC11943447; author attribution confirmed across all cited PMIDs

  • Only the all-L stereoisomer studied

    Low

    No published D-isomer/alternative-stereoisomer studies identified

  • Quality of unregulated products sold online

    High

    FDA (not approved)

Interaction summary(6)

Rated by direction with this peptide

  • Exogenous melatonin

    CautionTheoretical

    Epithalon stimulates endogenous melatonin synthesis (confirmed ~1.6-fold in the 75-women trial), so adding oral melatonin is largely redundant and additive and could over-shift circadian phase or increase sedation.

    Melatonergic mechanism, 2025 review PMC11943447

  • Thymalin (thymic peptide)

    SynergisticLow

    Co-administered with Epithalon/epithalamin in Khavinson-Korkushko geroprotector cohorts (n~266) with reported additive longevity and immune benefit. Backed by actual human co-administration data, so Low rather than Theoretical.

    Khavinson/Korkushko combination geroprotector studies

  • Standard cardiac therapy (antihypertensives / antianginals)

    ProtectiveLow

    In the Korkushko trials the pineal peptide (epithalamin EXTRACT, not the synthetic tetrapeptide) was added on top of unchanged standard cardiac therapy and improved cardiovascular outcomes with no adverse interaction reported. Direction reflects additive clinical benefit, not a pharmacological interaction.

    Korkushko RCT, PMID 22451889 / PMID 17426848 (epithalamin extract)

  • Active malignancy / chemotherapy (oncologic setting)

    CautionTheoretical

    Telomerase-activating mechanism is theoretically undesirable in patients with pre-existing cancer; no human oncologic safety data exist, so avoid pending evidence.

    Mechanism-based; telomerase data in 2025 review PMC11943447

  • CNS depressants / sedatives (benzodiazepines, alcohol)

    CautionTheoretical

    Raised endogenous melatonin could add modestly to sedation or next-morning grogginess when combined with other CNS depressants.

    Melatonergic mechanism, 2025 review PMC11943447

  • Antidiabetic / glucose-lowering agents

    CautionTheoretical

    Epithalamin has been reported to normalize carbohydrate and lipid metabolism in aged subjects, giving a theoretical additive glucose-lowering effect that warrants monitoring in treated diabetics. Rated Theoretical: the abstract of PMID 17426848 centers on cardiovascular/functional-age outcomes and does not itself document the glucose/lipid normalization, so the metabolic premise rests on the broader epithalamin geroprotector literature.

    Broader epithalamin geroprotector literature (Korkushko/Khavinson); PMID 17426848 is centered on CV/functional-age endpoints, not glucose metabolism

Known risks(5)

  • No large-scale safety studies in humans

  • Theoretical risk: telomerase activation could accelerate pre-existing cancer

  • Almost all human data from single Russian research group (no independent replication until 2025)

  • Only the all-L stereoisomer studied (7 other forms untested)

  • Quality of unregulated products sold online

Drug interactions(2)

  • Thymalin

    Combined use in Khavinson geroprotective study (n=266) showed additive longevity benefits

  • Melatonin

    Epithalon stimulates endogenous melatonin — exogenous melatonin may be redundant or additive

Research & benefits

Evidence base

Evidence Level
Mostly Preclinical
Total Studies
100
Human Studies
8

Mostly preclinical evidence, with small human studies of retinal outcomes and melatonin-related biomarkers. The cardiovascular mortality and larger geroprotection studies cited here used epithalamin extract, a different substance. Independent cell-culture research appeared in 2025.

Researched for(8)

Rated by confidence in the evidence

  • Telomerase activation

    Medium

    Human cell studies show telomeres lengthened about 33% and division continued past the normal limit.

    Vinogradova/Khavinson, PMID 12937682; 2025 review PMC11943447

  • Lifespan extension (animal models)

    Medium

    Animal studies report lifespan effects; the SHR mouse study increased maximum lifespan 12.3% but did not increase mean lifespan.

    Anisimov et al. SHR mice, PMID 14501183; 2025 review PMC11943447

  • Melatonin/circadian restoration

    Medium

    A study involving 75 middle-aged women found a 1.7-fold rise in urinary melatonin metabolite in the treated low-melatonin group; sleep outcomes were not measured.

    2025 review PMC11943447 (75-women sublingual trial confirmed); Korkushko epithalamin circadian studies

  • CV mortality reduction

    Low

    A multi-year trial of the related pineal extract epithalamin found lower cardiac mortality in elderly patients.

    Korkushko/Khavinson 15-yr follow-up RCT, PMID 22451889; PMID 17426848 (both epithalamin extract, not synthetic peptide)

  • Antitumor activity

    Low

    Animal data show fewer leukemias, though total tumor incidence was largely unchanged.

    Anisimov SHR tumor incidence, PMID 14501183 (total tumor incidence unchanged, only leukemia reduced); 2025 review PMC11943447 (HER-2/neu data)

  • Retinal protection

    Medium

    A 162-patient trial reported positive effects in about 90% of retinitis pigmentosa cases.

    Retinitis pigmentosa trial, PMID 12195242; 2025 review PMC11943447

  • Antioxidant protection

    Low

    Cell and animal studies show activation of Nrf2 and antioxidant enzymes like SOD and catalase.

    2025 review PMC11943447 (Drosophila, CBA mice, human fibroblast Nrf2 data)

  • Neuroprotection

    Low

    Lab and animal studies show less neuronal DNA damage and improved dendritic structure.

    2025 review PMC11943447 (SH-SY5Y, NB7, fibroblast-derived neurons, rat cortex)

Benefits(9)

  • Telomerase activation

  • Lifespan extension (animal models)

  • Melatonin/circadian restoration

  • CV mortality reduction

  • Antitumor activity

  • Retinal protection

  • Antioxidant protection

  • Neuroprotection

  • Immune modulation

Key studies(5)

  1. Khavinson VKh et al.

    Bull Exp Biol Med

    2003

    Reactivated telomerase in telomerase-negative human fibroblasts

  2. Anisimov VN et al.

    Biogerontology

    2003

    Maximum lifespan increased 12.3%; mean lifespan and total tumor incidence were unchanged. Leukemia development was reduced sixfold.

  3. Khavinson V et al.

    Neuro Endocrinol Lett

    2002

    Positive effects in 90% of 162 patients

  4. Korkushko OV et al.

    Bull Exp Biol Med

    2006

    Epithalamin extract, not synthetic epitalon, was associated with 28% lower overall mortality and twofold lower cardiovascular mortality over 12 years.

  5. Al-Dulaimi S et al.

    Biogerontology

    2025

    First independent confirmation of telomerase mechanism

What research suggests over time

  • Weeks 2-4

    Russian clinical use

    A small study reported changes in urinary melatonin metabolite and circadian-gene expression; improvement in sleep quality was not established.

  • Months 2-3

    Russian observational

    Melatonin pulse normalization and antioxidant enzyme upregulation reported in observational studies.

  • Long-term

    Preclinical + observational

    Animal data shows ~10-25% lifespan extension; human longevity claims are observational and Russia-only.

Regulation & availability

Why researchers look at it

Cultured human fibroblast studies reported telomerase activation and telomere elongation. Animal lifespan findings vary; the SHR study increased maximum lifespan but not mean lifespan. The 12-year mortality trial used epithalamin extract, not synthetic epitalon. Independent cell-culture research appeared in 2025. If broader research validates these results, Epithalon could become relevant to preventing age-related decline.

Estimated cost
No approved product and no verified reference price
FDA status
Epithalon is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Epithalon; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
WADA status
Epitalon is not named on the 2026 WADA Prohibited List. S0 prohibits pharmacological substances with no current governmental approval for human therapeutic use, unless another section applies; athletes should obtain a compound-specific determination from their anti-doping organization.
Prescribability
Epithalon is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Epithalon; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Availability
Unapproved in the US. Its nomination was withdrawn, and it is absent from current 503A Category 1 and the final bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. A clinic's offering does not show that it meets those conditions.

International status

  • EU

    Not approved

  • US

    Epithalon is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Epithalon; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.

  • Russia

    Used clinically (St. Petersburg Institute of Bioregulation)

Regulatory timeline(3)

  1. 2023-09
    FDA Category 2Restricted from compounding
  2. 2025
    First independent replicationAl-Dulaimi et al. confirmed telomerase mechanism (non-Russian group)
  3. 2026-10-28
    HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of epitalon acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

Is Epithalon safe?

Human safety is inadequately characterized, especially for subcutaneous injection. FDA identifies potential immunogenicity and impurity risks and found no clinical studies assessing safety.

How is it administered?

Subcutaneous or intramuscular injection in short courses. Intranasal and sublingual routes have also been studied.

Does it cause cancer?

Preclinical evidence suggests antitumor properties. 2025 study found ALT pathway in cancer cells instead of telomerase. Theoretical concern remains.

How strong is the evidence?

Compelling preclinically but limited clinically. Most human data from single Russian group. First independent replication 2025.

Can I legally obtain it in the US in 2026?

Epitalon is not FDA-approved and is not on FDA's compounding list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Unregulated products sold online are outside the policy.